Tips from Other Journals
Statins for Primary Prevention of Cardiovascular Disease
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2009 Dec 15;80(12):1492-1493.
Background: Cardiovascular disease is the most common cause of death and disability in the Western world. Statins are known to reduce the risk of death and further disability in persons with established cardiovascular disease; however, the risk reduction for those with risk factors but without diagnosed cardiovascular disease has not been clear. Brugts and colleagues conducted a meta-analysis of randomized controlled trials (RCTs) that focused on primary prevention or included subgroups of patients without known cardiovascular disease to clarify the role of statins in reducing all-cause mortality and the incidence of significant cardiovascular and cerebrovascular events.
The Study: The authors selected RCTs of statins versus controls (i.e., placebo, active control, or usual care) in at-risk patients. Studies were included if they had at least one year of follow-up; used death or cardiovascular events as primary outcomes; and enrolled at least 80 percent of patients without diagnosed cardiovascular disease or reported data separately on a sole primary prevention group.
Results: Of the 1,230 studies reviewed, 10 met the inclusion criteria and included 70,388 participants; 35,138 were randomized to the statin group and 35,250 to the control group. The mean age of participants was 63 years; 34 percent were women and 23 percent had diabetes. During a mean follow-up of 4.1 years, 5.1 percent of participants in the statin group died, compared with 5.7 percent in the control group, for a 12 percent relative risk reduction in all-cause mortality. Similarly, statin use was associated with a 30 percent relative risk reduction in major cardiovascular events, and a 19 percent relative risk reduction in major cerebrovascular events compared with the control group. There was no significant difference in cancer rates between the statin and control groups. These results did not vary much among men and women, patients older than 65 years, those 65 years and younger, and those with diabetes.
Conclusion: In patients with cardiovascular risk factors but without established cardiovascular disease, long-term statin use reduces the risk of death and cardiovascular morbidity. The relative risk reduction for primary prevention is similar to that reported for secondary prevention.
Brugts JJ, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. June 30, 2009;338:b2376.
Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions